Shire PLC (LON:SHP)‘s stock had its “overweight” rating restated by J P Morgan Chase & Co in a research note issued to investors on Monday. They currently have a GBX 6,000 ($75.90) price target on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target would suggest a potential upside of 40.27% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 6,400 ($80.96) target price on shares of Shire PLC in a research note on Wednesday, May 3rd. Berenberg Bank reiterated a “buy” rating on shares of Shire PLC in a research note on Wednesday, April 12th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a research note on Thursday, April 27th. Barclays PLC reiterated an “overweight” rating and issued a GBX 6,500 ($82.23) target price on shares of Shire PLC in a research note on Wednesday, May 3rd. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a GBX 6,100 ($77.17) target price on shares of Shire PLC in a research note on Friday, May 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of GBX 6,035.60 ($76.35).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON SHP) opened at 4313.00 on Monday. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The company’s market capitalization is GBX 38.99 billion. The company has a 50-day moving average price of GBX 4,581.69 and a 200 day moving average price of GBX 4,624.87.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/06/19/shire-plcs-shp-overweight-rating-reiterated-at-j-p-morgan-chase-co.html.

In other news, insider William Burns acquired 136 shares of the company’s stock in a transaction dated Friday, March 31st. The stock was bought at an average price of GBX 4,742 ($59.99) per share, with a total value of £6,449.12 ($8,158.28).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.